Meet Oncology Venture at SACHS Immuno-Oncology BD&L, Chicago; and at American Society of Clinical Oncology - ASCO, Chicago
APO010 Oncology Ventures FAS ligand, immuno-Oncology drug to be presented at SACHS ASSOCIATES Immuno-Oncology BD&L and Investment Forum.
ASCO, American Society of Clinical Oncology, ANNUAL MEETING. McCormick Place, Chicago, Illinois, USA.
Oncology Venture has a booth # 22102 as well as Face to Face meetings arranged.
Poster to be presented on the poster session ‘Breast Cancer—Metastatic’ Board 63; Abstract 1071 on the 4th of June 2017 at 8:00 AM-11:30 AM local time/15:00-18:30 CET
with the title:
“Retrospective-prospective blinded evaluation predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort”
For further information, please contact
CEO Peter Buhl Jensen, Adjunct professor, MD, PhD COO, IR&Comms Ulla Hald Buhl
Telephone: +45 21 60 89 22 Telephone +45 21 70 10 49
E-mail: email@example.com E-mail: firstname.lastname@example.org
About Oncology Venture Sweden AB
Oncology Venture Sweden AB is engaged in the research and development of anti-cancer drugs via its wholly owned Danish subsidiary Oncology Venture ApS. Oncology Venture has a license to use Drug Response Prediction – DRP™ – in order to significantly increase the probability of success in clinical trials. DRP™ has proven its ability to provide a statistically significant prediction of clinical outcomes from drug treatment in cancer patients in 29 of the 37 clinical studies that were examined. The Company uses a model that alters the odds in comparison with traditional pharmaceutical development. Instead of treating all patients with a particular type of cancer, patients’ tumors genes are screened first and only those who are most likely to respond to the treatment will be treated. Via a more well-defined patient group, the risk and costs are reduced while the development process becomes more efficient.
The current product portfolio: LiPlaCis® for Breast Cancer in collaboration with Cadila Pharmaceuticals, Irofulven developed from a fungus for prostate cancer and APO010 – an immuno-oncology product for Multiple Myeloma.
Oncology Venture has spun out two companies in Special Purpose Vehicles: 2X Oncology Inc. a US based company focusing on Precision medicine for women’s cancers with a pipeline of three promising phase 2 product candidates and Danish OV-SPV 2 will test and potentially develop an oral phase 2 Tyrosine Kinase inhibitor.